Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies
Launched by DANA-FARBER CANCER INSTITUTE · Aug 16, 2005
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking into the genetic factors that may increase the risk of developing certain types of blood cancers, such as non-Hodgkin's lymphoma, Hodgkin's disease, and chronic lymphocytic leukemia (CLL). Researchers want to understand if people in families with multiple cases of these cancers have different genetic traits compared to those who develop them without a family history. The study aims to create a tumor bank, which is a collection of tissue samples and medical data that can help identify specific genes linked to these diseases.
To participate in this study, individuals must be at least 18 years old and have been diagnosed with one of the cancers mentioned, along with having a close family member (like a parent, sibling, or child) who also has a lymphoproliferative disorder. Family members, whether they have cancer or not, can also join if they agree to participate. Even if a family member has passed away, their medical records may still be included with consent from their next of kin. Participants can expect to provide samples and information that will contribute to important research aimed at understanding these cancers better.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Any individual diagnosed with non-Hodgkin's lymphoma or Hodgkin's disease or chronic lymphocytic leukemia (CLL), who has a 1st degree relative (parent, sibling or child) with a lymphoproliferative disorder; or families in which the individual has a lymphoproliferative disorder, and an unusual clustering of frequent or premature solid tumors is also observed.
- • Family members of the individual, either affected or unaffected with lymphoma, who are contacted by the individual and agree to participate in the study.
- • Deceased family members may be included in the study. Public records such as death certificates may be used to confirm the history. Consent for medical records or tissue blocks will be obtained from the deceased family member's next of kin. The hierarchy of relatives defined as next of kin is spouse, offspring, parents and siblings. Archived tissue samples may be used for genetic research.
- • Age \> 18 years
- Exclusion Criteria:
- • Subjects without a family history of lymphoma
About Dana Farber Cancer Institute
The Dana-Farber Cancer Institute is a premier cancer research and treatment institution located in Boston, Massachusetts. Renowned for its commitment to advancing cancer care through innovative research, the institute integrates cutting-edge clinical trials with a multidisciplinary approach to patient care. With a focus on translating scientific discoveries into effective therapies, Dana-Farber collaborates with a network of leading researchers and healthcare professionals to improve outcomes for patients with cancer. The institute’s dedication to education, advocacy, and community engagement further underscores its mission to eradicate cancer and enhance the quality of life for those affected by the disease.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Patients applied
Trial Officials
Jennifer R. Brown, MD, PhD
Principal Investigator
Dana-Farber Cancer Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials